Time-Restricted High-Dose Melatonin for Acute Neuroprotection

Mechanistic description

Nightly 10mg melatonin dosing attenuates Aβ42-induced neurotoxicity through MT1-mediated suppression of PERK/CHOP apoptotic pathways. However, 10mg produces serum levels 20-100x physiological peaks—fundamentally different from H1’s physiological replacement framing. PERK/CHOP pathway studies used micromolar melatonin concentrations (100-500 μM) in cell culture; human CSF after 10mg oral peaks at 1-3 nM. Caspase-12 is predominantly murine—humans have non-functional pseudogene. ADCS melatonin trial found no benefit at doses up to 10mg. This hypothesis requires pharmacokinetic reconciliation and species-specific mechanism validation.

Evidence for (9)

Melatonin suppresses PERK/CHOP pathway in cellular Aβ toxicity models

PMID:22612506
Anti-apoptotic signaling demonstrated in rodent models

PMID:19641153
High-dose melatonin is safe in clinical trials

PMID:25963023
PMID:32150152 2020 pubmed
PMID:29395258 2018 pubmed
PMID:30793004 2019 pubmed
PMID:31246236 2019 pubmed
PMID:29512439 2019 pubmed
PMID:33238159 2020 pubmed

Evidence against (5)

10mg produces 20-100x physiological peak—contradicts H1's physiological framing

PMID:N/A
Cellular studies used 100-500 μM; human CSF reaches only 1-3 nM at 10mg oral

PMID:N/A
Caspase-12 is murine-specific; humans have non-functional pseudogene

PMID:N/A
ADCS trial showed no cognitive or biomarker benefit at 10mg

PMID:25963023
Multiple high-dose trials in MCI/AD failed to show disease-modifying effects

PMID:28799554

Evidence matrix

3 supporting 5 contradicting

47% posterior support

Supporting

Melatonin suppresses PERK/CHOP pathway in cellular Aβ toxicity models PMID:22612506
Anti-apoptotic signaling demonstrated in rodent models PMID:19641153
High-dose melatonin is safe in clinical trials PMID:25963023

Contradicting

10mg produces 20-100x physiological peak—contradicts H1's physiological framing PMID:N/A
Cellular studies used 100-500 μM; human CSF reaches only 1-3 nM at 10mg oral PMID:N/A
Caspase-12 is murine-specific; humans have non-functional pseudogene PMID:N/A
ADCS trial showed no cognitive or biomarker benefit at 10mg PMID:25963023
Multiple high-dose trials in MCI/AD failed to show disease-modifying effects PMID:28799554

Bayesian persona consensus

47% posterior support

1 signal · 0 for / 1 against · agreement 0%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Time-Restricted High-Dose Melatonin for Acute Neuroprotection. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-05-time-restricted-high-dose-melatonin-for-acute-ne-656de5768c

BibTeX

@misc{scidex_hypothesis_hsda2026,
  title        = {Time-Restricted High-Dose Melatonin for Acute Neuroprotection},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-05-time-restricted-high-dose-melatonin-for-acute-ne-656de5768c},
  note         = {SciDEX artifact hypothesis:h-SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913-05-time-restricted-high-dose-melatonin-for-acute-ne-656de5768c}
}